Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Jun 30
-
Benitec Biopharma (BNTC) Announces Appointment of Kishen Mehta to its Board of Directors
-
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
-
Disc Medicine (IRON) Announces 4.94M Share Offering at $36/sh
-
Disc Medicine Announces Underwritten Offering of Common Stock
-
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form 13F-NT Adage Capital Management For: Mar 31
-
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
-
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Form 4 ABEONA THERAPEUTICS INC. For: May 07 Filed by: Adage Capital Management, L.P.
-
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Abeona Therapeutics (ABEO) Prices 12.29M Share and Warrant Offering at $4.07/sh
-
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SC 13G EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form 3 EyePoint Pharmaceuticals For: Apr 18 Filed by: Adage Capital Management, L.P.
-
Benitec Biopharma (BNTC) Announces $40M Placement at $4.80/sh
-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
-
Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
-
Form SC 13G/A Benitec Biopharma Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Century Therapeutics (IPSC) to Acquire Clade Therapeutics, Announces $60M Private Placement
-
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
-
Form SC 13D ARCA biopharma, Inc. Filed by: Adage Capital Management, L.P.
-
Nkarta (NKTX) Prices $240M Share and Warrant Offering at $10/sh
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Geron Corp (GERN) Prices $150M Share and Warrant Offering at $3/sh
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Fate Therapeutics (FATE) Prices 14.55M Share Offering at $5.50/sh
-
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
-
Spyre Therapeutics (SYRE) announced $180M private placement
-
Spyre Therapeutics Announces $180 Million Private Placement
-
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
-
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Lexeo Therapeutics (LXEO) Announces Oversubscribed $95.0 Million Equity Financing
-
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Avidity Biosciences Inc. (RNA) Prices 15.22M Share Offering at $16.50/sh
-
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
-
Applied Therapeutics (APLT) Announces $100 Million Private Placement
-
Applied Therapeutics Announces $100 Million Private Placement
-
Crinetics Pharmaceuticals (CRNX) Announces 8.33M Share Offering at $42/sh
-
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
-
KalVista Pharmaceuticals (KALV): Adage Capital Partners Reports 6.87% Passive Stake
-
Form SC 13G Sable Offshore Corp. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.

